Hedge funds and other institutional investors have upped their short positions against Mesoblast Limited, a specialist in the development of regenerative medicine products operating in Australia, the United States, Singapore, the United Kingdom, and Switzerland, according to a report by MarketBeat.
As of 15 December, short interest in the company totalled 569,800 shares, an increase of 10.9% from the 30 November total of 513,700 shares.
BlackRock Inc is among the investors upping their positions having raised its holding in Mesoblast by 3.8% during Q3. BlackRock now owns 881,883 shares of the company’s stock valued at $2,245,000 after acquiring an additional 32,346 shares during the period. Ronit Capital also bought a new stake in Mesoblast in the third quarter worth about $382,000, while Balyasny Asset Management acquired $152,000 worth of shares during the third quarter.
Millennium Management meanwhile, raised its stake in shares of Mesoblast by 132.6% during the second quarter, and now owns 42,690 shares of the company’s stock valued at $95,000 after acquiring an additional 24,336 shares in the last quarter.
